Iovance Biotherapeutics, Inc. (IOVA)
After hours:
- Simply Wall St.
With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
- Insider Monkey
20 Counties with the Highest Cancer Rates in the US
In this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact of cancer, head straight to the 5 Counties with the Highest Cancer Rates in the US. Confronting Cancer: Global Impact and Trends in […]
- GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizuma
